focus -WSS

focus

author：knowledge 2025-08-28 06:24:28 - browse：628

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： NIH director takes cautious approach to Biden drug pricing priority

WSS

The EPA's new lead rule: How one expert crunched the numbers

How digital therapeutics firms are pivoting after Pear's bankruptcy

Takeda, Janssen join wearable maker to measure scratching

How to pay for weight loss drugs and save Medicare

Dewpoint Therapeutics lays off staff after losing partnerships

The EPA's new lead rule: How one expert crunched the numbers

entertainment

focus

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Independent physicians launch a new lobbying group

United colonoscopy coverage change 'may cost lives,' doctors say

Test for long Covid? Researchers find new clue in blood samples

Malaria cases in Florida and Texas: Here’s what you need to know

Biotech venture capitalists face new demands from investors

23andMe had bad news about my health. I wish a person had delivered it

As biotech industry slumps, bioscience job market is upside down

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cigna, Humana reportedly in talks to merge

leisure time

Copay coupons to count toward deductibles, after Biden court move

My yearlong odyssey to get my son’s ADHD medication covered

AI generated plenty of interest at JPM but not a lot of trust

Takeda, Janssen join wearable maker to measure scratching

Biotech venture capitalists face new demands from investors

Copay coupons to count toward deductibles, after Biden court move

focus

Wikipedia

focus

Wikipedia